BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

931 related articles for article (PubMed ID: 9166469)

  • 21. Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients.
    González FE; Ramírez M; Allerbring EB; Fasching N; Lundqvist A; Poschke I; Achour A; Salazar-Onfray F
    Immunobiology; 2014 Mar; 219(3):189-97. PubMed ID: 24192537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
    Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J
    Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines.
    Shilyansky J; Nishimura MI; Yannelli JR; Kawakami Y; Jacknin LS; Charmley P; Rosenberg SA
    Proc Natl Acad Sci U S A; 1994 Mar; 91(7):2829-33. PubMed ID: 7511820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells.
    Salazar-Onfray F; Nakazawa T; Chhajlani V; Petersson M; Kärre K; Masucci G; Celis E; Sette A; Southwood S; Appella E; Kiessling R
    Cancer Res; 1997 Oct; 57(19):4348-55. PubMed ID: 9331097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
    Ayyoub M; Rimoldi D; Guillaume P; Romero P; Cerottini JC; Valmori D; Speiser D
    Cancer Res; 2003 Sep; 63(17):5601-6. PubMed ID: 14500401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diversity and dominance among TCR recognizing HLA-A2.1+ influenza matrix peptide in human MHC class I transgenic mice.
    Man S; Ridge JP; Engelhard VH
    J Immunol; 1994 Nov; 153(10):4458-67. PubMed ID: 7963521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recognition of gp43 tumor-associated antigen peptide by both HLA-A2 restricted CTL lines and antibodies from melanoma patients.
    Takahashi T; Irie RF; Morton DL; Hoon DS
    Cell Immunol; 1997 Jun; 178(2):162-71. PubMed ID: 9225007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T-cell receptor repertoire of lymphocytes infiltrating cutaneous melanoma is predominated by V alpha specificities present in T-cells of normal human skin.
    Strohal R; Paucz L; Pehamberger H; Stingl G
    Cancer Res; 1994 Sep; 54(17):4734-9. PubMed ID: 8062272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes.
    Schiavetti F; Thonnard J; Colau D; Boon T; Coulie PG
    Cancer Res; 2002 Oct; 62(19):5510-6. PubMed ID: 12359761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. T-cell receptor repertoire in matched MART-1 peptide-stimulated peripheral blood lymphocytes and tumor-infiltrating lymphocytes.
    Cole DJ; Wilson MC; Rivoltini L; Custer M; Nishimura MI
    Cancer Res; 1997 Dec; 57(23):5320-7. PubMed ID: 9393756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
    Valmori D; Dutoit V; Liénard D; Rimoldi D; Pittet MJ; Champagne P; Ellefsen K; Sahin U; Speiser D; Lejeune F; Cerottini JC; Romero P
    Cancer Res; 2000 Aug; 60(16):4499-506. PubMed ID: 10969798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide.
    Valmori D; Gervois N; Rimoldi D; Fonteneau JF; Bonelo A; Liénard D; Rivoltini L; Jotereau F; Cerottini JC; Romero P
    J Immunol; 1998 Dec; 161(12):6956-62. PubMed ID: 9862730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase.
    Riley JP; Rosenberg SA; Parkhurst MR
    J Immunother; 2001; 24(3):212-20. PubMed ID: 11394498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overexpression of the T-cell receptor beta-chain variable region TCRBV14 in HLA-A2-matched primary human melanomas.
    Salvi S; Segalla F; Rao S; Arienti F; Sartori M; Bratina G; Caronni E; Anichini A; Clemente C; Parmiani G
    Cancer Res; 1995 Aug; 55(15):3374-9. PubMed ID: 7614474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.
    Valmori D; Fonteneau JF; Lizana CM; Gervois N; Liénard D; Rimoldi D; Jongeneel V; Jotereau F; Cerottini JC; Romero P
    J Immunol; 1998 Feb; 160(4):1750-8. PubMed ID: 9469433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New tumour-restricted melanoma antigens as defined by cytotoxic T-cell responses.
    Parmiani G; Anichini A; Castelli C
    Melanoma Res; 1997 Aug; 7 Suppl 2():S95-8. PubMed ID: 9578423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peptides with dual binding specificity for HLA-A2 and HLA-E are encoded by alternatively spliced isoforms of the antioxidant enzyme peroxiredoxin 5.
    Sensi M; Pietra G; Molla A; Nicolini G; Vegetti C; Bersani I; Millo E; Weiss E; Moretta L; Mingari MC; Anichini A
    Int Immunol; 2009 Mar; 21(3):257-68. PubMed ID: 19181932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
    Roszkowski JJ; Lyons GE; Kast WM; Yee C; Van Besien K; Nishimura MI
    Cancer Res; 2005 Feb; 65(4):1570-6. PubMed ID: 15735047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dominant TCR V alpha usage by virus and tumor-reactive T cells with wide affinity ranges for their specific antigens.
    Trautmann L; Labarrière N; Jotereau F; Karanikas V; Gervois N; Connerotte T; Coulie P; Bonneville M
    Eur J Immunol; 2002 Nov; 32(11):3181-90. PubMed ID: 12555663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma.
    Mackensen A; Ferradini L; Carcelain G; Triebel F; Faure F; Viel S; Hercend T
    Cancer Res; 1993 Aug; 53(15):3569-73. PubMed ID: 8339262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.